• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European review for medical and pharmacological sciences. >Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer
【24h】

Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer

机译：血清CA125，HE4和TK1联合检测在卵巢癌诊断中的应用价值研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To explore the diagnostic value of joint examination of cancer antigen 125 (CA125), thymidine kinase-1 (TK1) and human epididymis protein 4 (HE4) in the serum of patients with ovarian cancer. PATIENTS AND METHODS: A total of 75 ovarian cancer specimens (ovarian cancer group), 40 benign ovarian specimens (benign group) and 35 ovarian specimens of healthy women (normal control group) were collected. The serum levels of HE4, CA125 and TK1 and the positive detection rates in the three groups were compared. Meanwhile, the sensitivity and specificity of the three tumor markers in the diagnosis of ovarian cancer in the three groups were compared. RESULTS: The levels of HE4, CA125 and TK1 in the ovarian cancer group were significantly higher than those in the control group (p<0.05), and those in the ovarian cancer group were significantly higher than those in the benign group (p<0.05). The positive rates of CA125 as well as TK1 in the ovarian cancer group and the benign group were significantly higher than those in the control group (p<0.05), and those in the ovarian cancer group were significantly higher than those in the benign group (p<0.05). In the detection of an individual tumor marker, the sensitivity of CA125 was the highest, followed by HE4. The specificity of HE4 was the highest, followed by TK1. For the combination of two tumor markers, the sensitivity of CA125+HE4 ranked the first (92.18%), and the specificity of TK1+HE4 ranked the first (88.37%). The sensitivity and specificity of the joint detection of CA125+HE4+TK1 were 94.18% and 79.53%, respectively. The sensitivity of the joint detection of CA125+HE4+TK1 was significantly higher than that of the detection of a single tumor marker and that of joint detection of two tumor markers (p<0.05). CONCLUSIONS: Combined detection of CA125, HE4 and TK1 can significantly improve the sensitivity in the diagnosis of ovarian cancer.
机译：目的：探讨联合检查癌抗原125（CA125），胸苷激酶-1（TK1）和人附睾蛋白4（HE4）在卵巢癌患者血清中的诊断价值。患者与方法：收集了75例卵巢癌标本（卵巢癌组），40例良性卵巢标本（良性组）和35例健康女性的卵巢标本（正常对照组）。比较三组的血清HE4，CA125和TK1水平及阳性检出率。同时，比较了三种肿瘤标志物在三组卵巢癌诊断中的敏感性和特异性。结果：卵巢癌组HE4，CA125和TK1水平显着高于对照组（p <0.05），卵巢癌组HE4，CA125和TK1水平显着高于良性组（p <0.05）。 ）。卵巢癌组和良性组中CA125和TK1的阳性率显着高于对照组（p <0.05），卵巢癌组中的CA125和TK1的阳性率显着高于良性组（ p ＜0.05）。在检测单个肿瘤标记物中，CA125的敏感性最高，其次是HE4。 HE4的特异性最高，其次是TK1。对于两种肿瘤标记物的组合，CA125 + HE4的敏感性排名第一（92.18％），而TK1 + HE4的特异性排名第一（88.37％）。 CA125 + HE4 + TK1联合检测的灵敏度和特异性分别为94.18％和79.53％。 CA125 + HE4 + TK1联合检测的灵敏度显着高于单个肿瘤标记物的检测灵敏度和两个肿瘤标记物的联合检测灵敏度（p <0.05）。结论：CA125，HE4和TK1的联合检测可显着提高卵巢癌诊断的敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号